ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Accessing medicines
  • How medicines are priced in the UK
  • The future of medicine

The future of medicine

With 7,000 medicines and vaccines in the global pipeline, the future of health looks exciting. The pharmaceutical industry is pioneering new treatments and new technologies that will change the face of modern medicine. 

Medicines and vaccines have helped deliver incredible improvements in patient health – from doubling cancer survival in the last 40 years, reducing heart disease deaths by 75% since the 1960s and transforming HIV/AIDS into a chronic manageable condition.

The future of healthcare is an exciting one. 

Patients are increasingly benefitting from new and personalised treatments more complex conditions, like cancers and rare diseases.

Now more than ever we will need to work in partnership with our science partners, Government and the NHS to ensure that all patients are able to benefit from these new discoveries. 

How medicines are priced in the UK

  • How are new medicines developed?
  • How are medicines priced?
  • The Voluntary Scheme on branded medicines
  • What is the life cycle of a medicine?
  • What is the NICE Methods Review?
  • Improving access to medicine in the UK
  • The future of medicine
  • Supporting innovative medicines funding in Scotland
  • What was the PPRS?

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.